Drug Approvals International – Page 73 – All about Drugs Live by Dr Anthony Melvin Crasto

Dirithromycin

Dirithromycin LY 237216 LY-237216 (1R,2R,3R,6R,7S,8S,9R,10R,12R,13S,15R,17S)-9-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-3-ethyl-2,10-dihydroxy-7-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy}-15-[(2-methoxyethoxy)methyl]-2,6,8,10,12,17-hexamethyl-4,16-dioxa-14-azabicyclo[11.3.1]heptadecan-5-one UNII1801D76STL CAS number62013-04-1 Synthesis Reference Counter FT, Ensminger PW, Preston DA, Wu CY, Greene JM, Felty-Duckworth AM, Paschal JW, Kirst HA: Synthesis and antimicrobial evaluation of dirithromycin (AS-E 136; LY237216), a new macrolide antibiotic derived from erythromycin. Antimicrob Agents Chemother. 1991 Jun;35(6):1116-26. Pubmed. Dirithromycin CAS Registry Number: 62013-04-1 CAS Name: (1R,2R,3R,6R,7S,8S,9R,10R,12R,13S,15R,17S)-7-[(2,6-Dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl)oxy]-3-ethyl-2,10-dihydroxy-15-[(2-methoxyethoxy)methyl]-2,6,8,10,12,17-hexamethyl-9-[[3,4,6-trideoxy-3-(dimethylamino)-b-D-xylo-hexopyranosyl]oxy]-4,16-dioxa-14-azabicyclo[11.3.1]heptadecan-5-one Additional Names: [9S(R)]-9-deoxo-11-deoxy-9,11-[imino[2-(2-methoxyethoxy)ethylidene]oxy]erythromycin …

Brivudine

Brivudine ブリブジン; D07249 Zostex (TN) Formula C11H13BrN2O5 CAS 69304-47-8 Mol weight 333.1353 (E)-5-(2-Bromovinyl)-2′-deoxyuridine 2M3055079H 5-[(E)-2-bromoethenyl]-2′-deoxyuridine 5-[(E)-2-Bromovinyl]-2′-deoxyuridine 6267 69304-47-8 [RN] Brivudine CAS Registry Number: 69304-47-8 CAS Name: 5-[(1E)-2-Bromoethenyl]-2¢-deoxyuridine Additional Names: (E)-5-(2-bromovinyl)-2¢-deoxyuridine; brivudin; BVDU Trademarks: Brivex (Menarini); Brivirac (Menarini); Nervinex (Menarini); Zecovir (Guidotti); Zostex (Berlin-Chemie) Molecular Formula: C11H13BrN2O5 Molecular Weight: 333.14 Percent Composition: C 39.66%, H 3.93%, Br 23.99%, N 8.41%, O 24.01% Literature References: Analog …

Sinovac COVID-19 vaccine, CoronaVac,

Sinovac COVID-19 vaccine, CoronaVac, PiCoVacc CoronaVac, also known as the Sinovac COVID-19 vaccine,[1] is an inactivated virus COVID-19 vaccine developed by the Chinese company Sinovac Biotech.[2] It has been in Phase III clinical trials in Brazil,[3] Chile,[4] Indonesia,[5] the Philippines,[6] and Turkey.[7] It relies on traditional technology similar to BBIBP-CorV and BBV152, other inactivated-virus COVID-19 vaccines in Phase III trials.[8] CoronaVac does not need to be frozen, and both the vaccine and raw material for …

Sputnik V, Gam-COVID-Vac, Gamaleya

Sputnik V Gam-COVID-Vac Gamaleya SARS-CoV-2 Gam-COVID-Vac Lyo Gam-COVID-Vac was created by Gamaleya Research Institute of Epidemiology and MIcrobiology in Russia. The vaccine candidate is a heterologous COVID-19 vaccine containing two components, recombinant adenovirus type 26 (rAd26) vector and recombinant adenovirus type 5 (rAd5) vector which both carry the SARS-CoV-2 spike glycoprotein. The vaccine is …

Johnson & Johnson COVID-19 vaccine, JNJ 78436735

Johnson & Johnson COVID-19 vaccine, JNJ 78436735 Ad26.COV2.S JNJ-78436735 Ad26COVS1 VAC31518 UNII: JT2NS6183B https://www.onesourcedocs.com/wp-content/uploads/2021/03/Janssen_Pharmaceuticals_SDS_Ad26COVS1_100000015774_v3_5_202102_nr-1.pdf NAME DOSAGE STRENGTH ROUTE LABELLER MARKETING START MARKETING END Covid-19 Vaccine Janssen Injection, suspension 0.95 Inf. U Intramuscular Janssen Cilag International Nv 2021-03-17 Not applicable Janssen COVID-19 Vaccine Injection, suspension 50000000000 {VP}/0.5mL Intramuscular Janssen Products, LP 2021-01-04 Not applicable NAME INGREDIENTS …

NOVAWAX, NVX-CoV2373,

NOVAWAX NVX-CoV2373 SARS-CoV-2 rS Nanoparticle Vaccine MCDC OTA agreement number W15QKN-16-9-1002 Novavax COVID-19 vaccine, Coronavirus disease 19 infection SARS-CoV-2 rS, TAK 019 Novavax, Inc. is an American vaccine development company headquartered in Gaithersburg, Maryland, with additional facilities in Rockville, Maryland and Uppsala, Sweden. As of 2020, it had an ongoing Phase III clinical trial in older adults for its candidate vaccine for seasonal influenza, NanoFlu and a candidate vaccine (NVX-CoV2373) …

BBIBP-CorV, Sinopharm COVID-19 vaccine

BBIBP-CorV, Sinopharm COVID-19 vaccine CAS Number 2503126-65-4 Inactivated novel coronavirus (2019-CoV) vaccine (Vero cells) Purified inactivated SARS-CoV-2 Vaccine ref Lancet Infectious Diseases (2021), 21(1), 39-51. BBIBP-CorV, also known as the Sinopharm COVID-19 vaccine,[1] is one of two inactivated virus COVID-19 vaccines developed by Sinopharm. In late December 2020, it was in Phase III trials in Argentina, Bahrain, Egypt, Morocco, Pakistan, Peru, and the United Arab Emirates (UAE) with over 60,000 participants.[2] On December 9, the …

Sitravatinib

Sitravatinib 1-N‘-[3-fluoro-4-[2-[5-[(2-methoxyethylamino)methyl]pyridin-2-yl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 1-N’-[3-fluoro-4-[2-[5-[(2-methoxyethylamino)methyl]pyridin-2-yl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide MG-91516 1,1-Cyclopropanedicarboxamide, N-[3-fluoro-4-[[2-[5-[[(2-methoxyethyl)amino]methyl]-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxy]phenyl]-N’-(4- fluorophenyl)- N-(3-fluoro-4-((2-(5-(((2-methoxyethyl)amino)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide シトラバチニブ; ситраватиниб , سيترافاتينيب , 司曲替尼 , Formula C33H29F2N5O4S Cas 1123837-84-2 Mol weight 629.6763 MG-516 Sitravatinib (MGCD516) UNII-CWG62Q1VTB CWG62Q1VTB MGCD-516 MGCD516 Antineoplastic, Receptor tyrosine kinase inhibitor Sitravatinib (MGCD516) is an experimental drug for the treatment of cancer. It is a small molecule inhibitor of multiple tyrosine kinases. Sitravatinib is being developed by Mirati Therapeutics.[1] Ongoing phase II …

Moderna COVID-19 vaccine, mRNA 1273

Moderna COVID-19 vaccine, mRNA 1273 CAS 2457298-05-2 An mRNA vaccine against SARS-CoV-2 expressing the prefusion-stabilized SARS-CoV-2 spike trimer MRNA-1273 SARS-COV-2 CX 024414 CX-024414 CX024414 mRNA-1273 NAME DOSAGE STRENGTH ROUTE LABELLER MARKETING START MARKETING END Covid-19 Vaccine Moderna Injection Intramuscular Moderna Therapeutics Inc 2020-12-23 Not applicable Moderna COVID-19 Vaccine Injection, suspension 0.2 mg/1mL Intramuscular Moderna US, Inc. …

Anamorelin hydrochloride

Anamorelin 249921-19-5 [RN] 3-{(2R)-3-{(3R)-3-Benzyl-3-[(trimethylhydrazino)carbonyl]-1-piperidinyl}-2-[(2-methylalanyl)amino]-3-oxopropyl}-1H-indole 3-Piperidinecarboxylic acid, 1-[(2R)-2-[(2-amino-2-methyl-1-oxopropyl)amino]-3-(1H-indol-3-yl)-1-oxopropyl]-3-(phenylmethyl)-, 1,2,2-trimethylhydrazide, (3R)- 8846 анаморелин أناموريلين 阿那瑞林 Formula C31H42N6O3 Molar mass 546.716 g·mol−1 .HCL Anamorelin hydrochloride 3-Piperidinecarboxylic acid, 1-[(2R)-2-[(2-amino-2-methyl-1-oxopropyl)amino]-3-(1H-indol-3-yl)-1-oxopropyl]-3-(phenylmethyl)-, 1,2,2- trimethylhydrazide, hydrochloride (1:1), (3R)- Formula C31H42N6O3. HCl CAS 861998-00-7 Mol weight 583.1645 APPROVED JAPAN PMDA Adlumiz, 22/1/2021 アナモレリン塩酸塩 ONO-7643, RC-1291, ST-1291 Antineoplastic, Growth hormone secretagogue receptor (GHSR) agonist Anamorelin is a non-peptidic ghrelin mimetic Treatment …